Epcoritamab — Drug Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

6 Recruiting

10 Completed trials

9 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 6 Phase II/III: 1 Phase II: 5 Phase I/II: 5 Phase I (Other): 1 Phase I (FiH): 2

Oversight events:

3 serious breaches 1 urgent safety measure across 3 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 4 Follicular lymphoma 3 B-cell lymphoma refractory 2 High-grade B-cell lymphoma 2 Nodal marginal zone B-cell lymphoma 1 Follicle centre lymphoma follicular grade I II III refractory 1 Marginal zone lymphoma 1 Waldenstrom´s macroglobulinaemia recurrent 1 Extranodal marginal zone B-cell lymphoma (MALT type) 1 Waldenstrom's macroglobulinaemia 1 Diffuse large B-cell lymphoma refractory 1 Splenic marginal zone lymphoma 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 6 Genmab A/S 5 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 2 Universitaet Muenster 2 Daiichi Sankyo Inc. 1 Fundacion Geltamo 1 LYSARC 1 Universitaetsklinikum Ulm AöR 1 University Of Cologne 1

All trials

20 total

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised

2023-509861-19-00 Phase II 1 country Universitaet Muenster
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending

2024-513445-37-00 Phase III 4 countries University Of Cologne
A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending

2025-522595-87-00 Phase I (FiH) 2 countries Daiichi Sankyo Inc.
Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1) Pending

2025-524879-23-00 Phase II 1 country Universitaetsklinikum Ulm AöR
HOVON 178 WM: Treatment of Waldenstrom’s macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment Recruiting

2025-522295-91-00 Phase I/II 3 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Phase III 16 countries AbbVie Deutschland GmbH & Co. KG
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 Phase II 1 country Universitaet Muenster
Response-adaptive to Epcoritamab In FIrst Relapse: A Phase II, response-adaptive, Open-Label, Multicenter Study to Evaluate the Efficacy of … Recruiting

2024-514440-86-00 Phase II 1 country Fundacion Geltamo
A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit… Recruiting

2023-505834-84-00 Phase II/III 1 country Lysarc
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting

2022-500305-40-00 Phase I/II 4 countries Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Phase III 11 countries AbbVie Deutschland GmbH & Co. KG
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended

2023-505628-67-00 Phase III 14 countries AbbVie Deutschland GmbH & Co. KG
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Ended

2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 Phase III 13 countries Genmab A/S
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Phase I/II 9 countries Genmab A/S
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries Genmab A/S
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 Phase II 8 countries Genmab A/S
This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B… Ended

2023-504795-20-00 Phase I (Other) 6 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–20 of 20 trials

← All drugs A–Z